Regenxbio (RGNX) Liabilities and Shareholders Equity (2014 - 2026)
Regenxbio (RGNX) posted quarterly Liabilities and Shareholders Equity of $453.0 million for Q4 2025, down 2.78% year-over-year from $466.0 million in Q4 2024, and down 13.74% quarter-over-quarter from $525.2 million in Q3 2025.
Regenxbio (RGNX) Liabilities and Shareholders Equity (2014 - 2026) Analysis & Trends
Regenxbio's Liabilities and Shareholders Equity history runs 12 years deep, the most recent figure standing at $453.0 million for Q4 2025.
- In Q4 2025, Liabilities and Shareholders Equity fell 2.78% year-over-year to $453.0 million; the TTM figure through Dec 2025 stood at $2.1 billion (down 6.11% YoY), while the FY2025 annual figure was $453.0 million, down 2.78% from the prior year.
- Liabilities and Shareholders Equity for Q4 2025 stood at $453.0 million, down from $525.2 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $1.1 billion in Q4 2021, with the low at $453.0 million in Q4 2025.
- The 5-year median for Liabilities and Shareholders Equity is $658.1 million (2023), against an average of $709.9 million.
- The sharpest annual moves came in 2021 and 2023: Liabilities and Shareholders Equity jumped 89.56% in 2021, then plunged 31.12% in 2023.
- Regenxbio's Liabilities and Shareholders Equity stood at $1.1 billion in 2021, then dropped by 25.19% to $833.3 million in 2022, then sank by 31.12% to $574.0 million in 2023, then dropped by 18.81% to $466.0 million in 2024, then fell by 2.78% to $453.0 million in 2025.
- Business Quant data shows RGNX's Liabilities and Shareholders Equity at $453.0 million in Q4 2025, $525.2 million in Q3 2025, and $581.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Regenxbio | 583.35 Mn | 477.83 Mn | 106.98 Mn | 386.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 386.62 Mn |
| Dec 31, 2025 | 453.03 Mn |
| Sep 30, 2025 | 525.20 Mn |
| Jun 30, 2025 | 581.03 Mn |
| Mar 31, 2025 | 490.93 Mn |
| Dec 31, 2024 | 465.99 Mn |
| Sep 30, 2024 | 519.11 Mn |
| Jun 30, 2024 | 569.38 Mn |
| Mar 31, 2024 | 629.22 Mn |
| Dec 31, 2023 | 573.97 Mn |
| Sep 30, 2023 | 633.79 Mn |
| Jun 30, 2023 | 682.46 Mn |
| Mar 31, 2023 | 747.83 Mn |
| Dec 31, 2022 | 833.27 Mn |
| Sep 30, 2022 | 883.79 Mn |
| Jun 30, 2022 | 953.44 Mn |
| Mar 31, 2022 | 1.03 Bn |
| Dec 31, 2021 | 1.11 Bn |
| Sep 30, 2021 | 800.40 Mn |
| Jun 30, 2021 | 836.40 Mn |